CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

TAKEDA PHARMACEUTICAL CO LTD

TKPHF
$47.70B
Large Cap
NASDAQBiotechnology🇺🇸North America47.5K employees

Drugs in Pipeline

92

Phase 3 Programs

68

Upcoming Catalysts

7

Next Catalyst

Next month

Market Overview

Stock performance and key metrics

TKPHF News
Catalyst Timeline

7 upcoming, 1 past

Drug Pipeline

Epoetin Alfa

Phase 3

Myelodysplastic Syndrome

rVWF

Phase 3

Von Willebrand Disease (VWD)

TAK-928

Phase 3

IO-resistant sqNSCLC

TAK-875

Phase 3

Diabetes Mellitus

Alogliptin and pioglitazone

Phase 3

Type 2 Diabetes Mellitus

TVP-1012 1mg

Phase 3

Parkinson's Disease

Vedolizumab SC

Phase 3

Colitis, Ulcerative

Lapaquistat acetate

Phase 3

Hypercholesterolemia

TAK-788

Phase 3

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

TAP-144-SR(6M)

Phase 3

Premenopausal Breast Cancer

Teduglutide

Phase 3

Short Bowel Syndrome

Mezagitamab

Phase 3

Kidney Disease

Tetravalent Dengue Vaccine (TDV)

Phase 3

Dengue Fever

Pioglitazone and metformin

Phase 3

Diabetes Mellitus

TAK-881

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Allopurinol

Phase 3

Gout

omega-3-acid ethyl esters 90 (TAK-085)

Phase 3

Hypertriglyceridemia

TAK-625

Phase 3

Progressive Familial Intrahepatic Cholestasis (PFIC)

TAK-861

Phase 3

Narcolepsy Type 1

Lanadelumab

Phase 3

Hereditary Angioedema (HAE)

TAK-019

Phase 3

Coronavirus Disease (COVID-19)

Valsartan

Phase 3

Hypertension

Elritercept

Phase 3

Myelodysplastic Syndromes

Azilsartan medoxomil with or without add-on chlorthalidone

Phase 3

Hypertension

rozerem

Phase 3

Insomnia

Ponatinib

Phase 3

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Relugolix

Phase 3

Uterine Fibroids

Apremilast

Phase 3

Plaque Psoriasis

Bismuth-Containing Quadruple Therapy

Phase 3

Gastric Ulcer

Vedolizumab IV

Phase 3

Ulcerative Colitis

Vortioxetine

Phase 3

Depressive Disorder, Major

TAK-438

Phase 3

Duodenal Ulcer

Lansoprazole

Phase 3

Gastric Ulcers

Alogliptin

Phase 3

Type 2 Diabetes Mellitus

Vedolizumab

Phase 3

Ulcerative Colitis

Zasocitinib

Phase 3

Plaque Psoriasis

Febuxostat

Phase 3

Hyperuricosuria

Ramelteon

Phase 3

Chronic Insomnia

TDV

Phase 3

Healthy Volunteers

Lubiprostone

Phase 3

Chronic Idiopathic Constipation

Febuxostat IR

Phase 3

Gout

Lapaquistat acetate and atorvastatin

Phase 3

Dyslipidemia

TAK-360

Phase 3

Narcolepsy Type 2

Vonoprazan

Phase 3

Helicobacter Pylori

Alogliptin and insulin

Phase 3

Diabetes Mellitus

Alogliptin and metformin

Phase 3

Diabetes Mellitus

Trelagliptin 25 mg

Phase 3

Type 2 Diabetes Mellitus

ciclesonide (XRP1526)

Phase 3

Respiratory Tract Diseases

Alogliptin 25 mg

Phase 3

Diabetes Mellitus

IGI, 10%

Phase 3

Multiple Myeloma

Soticlestat

Phase 3

15q Duplication Syndrome

Alogliptin and voglibose

Phase 3

Type 2 Diabetes Mellitus

SYR-472

Phase 3

Type 2 Diabetes Mellitus

Dexlansoprazole MR

Phase 3

Esophagitis, Reflux

Dexlansoprazole

Phase 3

Gastroesophageal Reflux Disease (GERD)

TAK-771

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Fazirsiran Injection

Phase 3

Alpha1-Antitrypsin Deficiency

Ixazomib

Phase 3

Multiple Myeloma

Maribavir

Phase 3

Cytomegalovirus (CMV)

Azilsartan medoxomil

Phase 3

Hypertension

TAK-279

Phase 3

Ulcerative Colitis

Azilsartan medoxomil and chlorthalidone

Phase 3

Safety

Chlorthalidone

Phase 3

Hypertension

Actovegin

Phase 3

Post-Stroke Cognitive Impairment (PSCI)

Peginesatide

Phase 3

Anemia

Darvadstrocel

Phase 3

Complex Perianal Fistulas in Adult Participants With Crohn's Disease

Azilsartan

Phase 3

Pediatric Hypertension

HYQVIA

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

TAK-935

Phase 2

Epilepsy

Vedolizumab 300 MG Injection [Entyvio]

Phase 2

Immune Checkpoint Inhibitor-Related Colitis

TAK-850

Phase 2

Influenza

Idursulfase-IT

Phase 2

Hunter Syndrome

TAK-226

Phase 2

Myelodysplastic Syndromes

TAK-583

Phase 2

Diabetic Neuropathies

TAK-079

Phase 2

Myasthenia Gravis

TAK-385

Phase 2

Endometriosis

Immune Globulin Infusion (Human), 10% Solution

Phase 2

Hematologic Malignancies

Tak-228 & Tak-117

Phase 2

Triple Negative Breast Cancer

Adcetris-Levact

Phase 2

Clinical Efficacy

Brentuximab Vedotin

Phase 2

Hodgkin Disease

Ramelteon and gabapentin

Phase 2

Sleep Initiation and Maintenance Disorders

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

Phase 2

Colorectal Carcinoma

Rusfertide

Phase 2

Polycythemia Vera

Voglibose

Phase 2

Diabetes Mellitus, Type 2

Niraparib

Phase 2

Ovarian Cancer

Glimepiride

Phase 2

Diabetes Mellitus, Type 2

TAK-954

Phase 2

Diabetic Gastroparesis

Brigatinib

Phase 2

NSCLC

TAK-755

Phase 2

Thrombotic Thrombocytopenic Purpura (TTP)

Namilumab

Phase 2

Plaque Psoriasis

TAK-505

Phase 2

Malignant Solid Tumors

NoV GI.1/GII.4 Bivalent VLP Vaccine

Phase 2

Healthy Volunteers

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Market-Implied Move
Regulatory Approvals

Frequently asked questions

What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?

CatalystAlert tracks 92 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) pipeline across Phase 3, Phase 2. Its lead program is Epoetin Alfa (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?

TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) next tracked catalyst is a Phase 2 expected September 18, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TKPHF biotech catalysts?

Add TKPHF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply